scholarly journals Organ recovery from deceased donors with prior COVID‐19: A case series

Author(s):  
Nikole A. Neidlinger ◽  
Jeannina A. Smith ◽  
Anthony M. D’Alessandro ◽  
David Roe ◽  
Tim E. Taber ◽  
...  
2019 ◽  
Vol 41 (4) ◽  
pp. 534-538 ◽  
Author(s):  
Guilherme Palhares Aversa Santos ◽  
Luis Gustavo Modelli de Andrade ◽  
Mariana Farina Valiatti ◽  
Mariana Moraes Contti ◽  
Hong Si Nga ◽  
...  

ABSTRACT Introduction: The number of incident and prevalent patients on dialysis has increased, as well as the number of candidates for renal transplantation in Brazil, without a proportional increase in the number of organ donors. The use of expanded kidneys, as to renal function, may be an alternative to increase the supply of organs. Objective: to discuss the feasibility of using expanded kidneys for renal function, which are in severe acute renal injury. Methods: All cases of renal transplantation of deceased donors performed at the Hospital das Clínicas de Botucatu of UNESP, from January 2010 to June 2018, totaling 732 cases were evaluated. Cases with final donor creatinine greater than 6 mg/dL were selected. Results: four patients were selected, of whom all donors were in severe acute kidney injury (AKI). These donors presented rhabdomyolysis as a probable cause of severe AKI, were young, with no comorbidities and had decreased urinary volume in the last 24 hours. The clinical evolution of all the recipients was satisfactory, with a glomerular filtration rate after transplantation ranging from 48 to 98 mL/min/1.73 m2. Conclusion: this series of cases shows the possibility of using renal donors in severe AKI, provided the following are respected: donor age, rhabdomyolysis as the cause of AKI, and implantation-favorable biopsy findings. Additional studies with better designs, larger numbers of patients and longer follow-up times are needed.


2012 ◽  
Vol 44 (6) ◽  
pp. 1644-1647 ◽  
Author(s):  
M. Yilmaz ◽  
T. Piskin ◽  
S. Akbulut ◽  
V. Ersan ◽  
F. Gonultas ◽  
...  

2012 ◽  
Vol 94 (10S) ◽  
pp. 526
Author(s):  
M. Kosieradzki ◽  
J. Czerwinski ◽  
A. Jakubowska-Winecka ◽  
T. Kubik ◽  
A. Kobryn ◽  
...  

2012 ◽  
Vol 94 (10S) ◽  
pp. 207
Author(s):  
M. Kosieradzki ◽  
J. Czerwinski ◽  
A. Jakubowska-Winecka ◽  
T. Kubik ◽  
A. Kobryn ◽  
...  

2012 ◽  
Vol 44 (7) ◽  
pp. 2173-2175 ◽  
Author(s):  
S.C.B. Wejda ◽  
M. Kosieradzki ◽  
A. Jakubowska-Winecka ◽  
J. Czerwinski ◽  
A. Kobryn ◽  
...  

2020 ◽  
Vol 31 (11) ◽  
pp. 2678-2687 ◽  
Author(s):  
Meghan E. Sise ◽  
David S. Goldberg ◽  
Jens J. Kort ◽  
Douglas E. Schaubel ◽  
Rita R. Alloway ◽  
...  

BackgroundSingle-center trials and retrospective case series have reported promising outcomes using kidneys from donors with hepatitis C virus (HCV) infection. However, multicenter trials are needed to determine if those findings are generalizable.MethodsWe conducted a prospective trial at seven centers to transplant 30 kidneys from deceased donors with HCV viremia into HCV-uninfected recipients, followed by 8 weeks of once-daily coformulated glecaprevir and pibrentasvir, targeted to start 3 days posttransplant. Key outcomes included sustained virologic response (undetectable HCV RNA 12 weeks after completing treatment with glecaprevir and pibrentasvir), adverse events, and allograft function.ResultsWe screened 76 patients and enrolled 63 patients, of whom 30 underwent kidney transplantation from an HCV-viremic deceased donor (median kidney donor profile index, 53%) in May 2019 through October 2019. The median time between consent and transplantation of a kidney from an HCV-viremic donor was 6.3 weeks. All 30 recipients achieved a sustained virologic response. One recipient died of complications of sepsis 4 months after achieving a sustained virologic response. No severe adverse events in any patient were deemed likely related to HCV infection or treatment with glecaprevir and pibrentasvir. Three recipients developed acute cellular rejection, which was borderline in one case. Three recipients developed polyomavirus (BK) viremia near or >10,000 copies/ml that resolved after reduction of immunosuppression. All recipients had good allograft function, with a median creatinine of 1.2 mg/dl and median eGFR of 57 ml/min per 1.73 m2 at 6 months.ConclusionsOur multicenter trial demonstrated safety and efficacy of transplantation of 30 HCV-viremic kidneys into HCV-negative recipients, followed by early initiation of an 8-week regimen of glecaprevir and pibrentasvir.


2005 ◽  
Vol 5 (5) ◽  
pp. 1105-1110 ◽  
Author(s):  
Martin D. Jendrisak ◽  
Keith Hruska ◽  
Jessica Wagner ◽  
Dianne Chandler ◽  
Dean Kappel

2018 ◽  
Vol 24 ◽  
pp. 202-203
Author(s):  
Mireya Perez-Guzman ◽  
Alfredo Nava de la Vega ◽  
Arturo Pena Velarde ◽  
Tania Raisha Torres Victoria ◽  
Froylan Martinez-Sanchez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document